In recognition of the pioneering work of Angela McAvoy AM who founded Crohn’s & Colitis Australia (CCA), a Research Scholarship of $25,000 per year for 3 years is offered in 2019 with commencement in early 2020.
The purpose of this Scholarship is to foster the development of a health professional or scientist in clinical research into inflammatory bowel disease in Australia. Funds to support this scholarship were entirely raised by CCA through donations from people living with inflammatory bowel disease (IBD) their family friends and public donors supporting them.
The applicant must:
- be an Australian citizen or hold permanent Australian resident status;
- enrolled in or holding a higher research degree (e.g. PhD, MD);
- have shown an ability to successful carry out clinical research; and
- outline a research proposal that specifically applies to clinical aspects of patients with inflammatory bowel disease. Preference is given to proposals for work that complies with the priority areas of CCA as listed below:
- Better disease management and improved well being
- Applications Open: Friday 11 October 2019
- Applications Close: Friday 8 November 2019
- E-mail: firstname.lastname@example.org
Dr Antonina Mikocka-Walus
CCA’s inaugural $150,000 Angela McAvoy AM Fellowship was awarded to Dr Antonina Mikocka-Walus in 2009 for her study into whether cognitive behavioural therapy (CBT) can improve the psychological and clinical outcomes in IBD.
Her research found that CBT was effective in reducing the number of people with poor coping with IBD at six and 12 months and increasing the number of people who are confident in actively managing the disease at 12 months.
IBD Unit, Monash Medical Centre
In November 2012, CCA awarded the second Angela McAvoy Research Fellowship to the IBD Unit of Monash Medical Centre and Monash University to undertake a study entitled Mesenteric Fat, Adipocytokines and Sarcopenia in Crohn’s Disease, with Dr Gregory Moore as lead researcher.
With increasing numbers of overweight and obese individuals in the Crohn’s population, the study aims to identify the role that visceral fat and its metabolic and immunological effects have on Crohn’s disease and identify new therapeutic targets and biomarkers to predict more severe disease.